Next Steps for Immunotherapies, Cell Therapies in Oncology Next Steps for Immunotherapies, Cell Therapies in Oncology
At ESMO 2017, Drs Zimmermann, Svane, and Coukos discuss successes and setbacks in immuno-oncology.Medscape Oncology
Researchers believe an assay may be used to detect and monitor dynamics of genetic mutations of patients treated with immunotherapy.
The STRIvE-01 study explored the safety of CAR T-cell therapy in children and young adults with relapsed or refractory solid tumors.
This article provides an overview of AZD1775, based on English peer-reviewed articles on MEDLINE. The authors highlight the data from the published preclinical and clinical studies. Expert opinion: A majority of the current clinical trials focus on AZD1775 combined with chemotherapy or radiation. Treatment with AZD1775 was tolerated and antitumor activity has been observed, especially in patients with advanced malignancies harboring G1 checkpoint aberrations and/or DNA damage repair defects. Thus, identification of the molecular subtypes that benefit most from the treatment with AZD1775 alone or in combination may provide ...
Dr Jing Pan, of Beijing Boren Hospital, Beijing, P.R. China, discusses a new anti-CD22 CAR T-cell immunotherapy for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). Dr Pan ex... Author: VJHemOnc Added: 08/15/2018
One of the major downsides to immunotherapy is its high cost. In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses whether it is cost-effective for patients to receive mon... Author: VJHemOnc Added: 08/15/2018
Publication date: Available online 15 August 2018Source: Pharmacological ResearchAuthor(s): Robert RoskoskiAbstractThe Ras-Raf-MEK-ERK signal transduction cascade is arguably the most important oncogenic pathway in human cancers. Ras-GTP promotes the formation of active homodimers or heterodimers of A-Raf, B-Raf, and C-Raf by an intricate process. These enzymes are protein-serine/threonine kinases that catalyze the phosphorylation and activation of MEK1 and MEK2 which, in turn, catalyze the phosphorylation and activation of ERK1 and ERK2. The latter catalyze the regulatory phosphorylation of dozens of cytosolic and nuclear...
Publication date: September–October 2018Source: Journal of the American Society of Cytopathology, Volume 7, Issue 5Author(s): Maryan Shabihkhani, Weiming Yang, Minghui Ao, Edward Gabrielson, Frederic Askin, Hui Zhang, Q. Kay Li
Publication date: September–October 2018Source: Journal of the American Society of Cytopathology, Volume 7, Issue 5Author(s): Jordan Reynolds, Longmei Zhao
araman Ö, Uzuner N Abstract Işık S, Çağlayan-Sözmen Ş, Asilsoy S, Kılıçarslan SK, Anal Ö, Karaman Ö, Uzuner N. Knowledge levels related to allergen specific immunotherapy and perspectives of parents whose children were diagnosed with asthma and/or allergic rhinitis in Turkey. Turk J Pediatr 2018; 60: 50-55. In the present study, we aimed to evaluate the knowledge levels and perspectives about allergen specific immunotherapy (ASI) of parents whose children were diagnosed with asthma and/or allergic rhinitis with positive skin prick test. The study was conducted between Septem...
(NIH/National Cancer Institute) Steven A. Rosenberg, M.D., Ph.D., of the Center for Cancer Research (CCR) at the National Cancer Institute (NCI), has been named a recipient of the 2018 Albany Medical Center Prize in Medicine and Biomedical Research for his leading role in the development of immunotherapy to treat cancer. Dr. Rosenberg will share the honor with fellow immunotherapy researchers James P. Allison, Ph.D., and Carl H. June, M.D.